Rogel Cancer Center: University of Michigan

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary

Established: 1991-01-01

Employees: -

Market Cap: -

Website: http://www.rogelcancercenter.org

Clinical Trials

Trabectedin in Combination With Olaparib in Advanced Unresectable or Metastatic Sarcoma

Phase 2

Active, not recruiting

Conditions: Sarcoma
Sarcoma Metastatic

Interventions: Drug: Olaparib
Drug: Trabectedin

First Posted Date: 2019-09-03

Last Posted Date: 2024-07-29

Lead Sponsor: University of Michigan Rogel Cancer Center

Target Recruit Count: 29

Registration Number: NCT04076579

Locations: 🇺🇸
University of Michigan Rogel Cancer Center, Ann Arbor, Michigan, United States

Gemcitabine in Newly-Diagnosed Diffuse Midline Glioma

Early Phase 1

Withdrawn

Conditions: Glial Tumor of Brain
Diffuse Intrinsic Pontine Glioma
Glioma

Interventions: Drug: Gemcitabine
Procedure: Tumor biopsy and blood draw

First Posted Date: 2019-08-09

Last Posted Date: 2019-11-27

Lead Sponsor: University of Michigan Rogel Cancer Center

Registration Number: NCT04051047

Locations: 🇺🇸
The University of Michigan Rogel Cancer Center, Ann Arbor, Michigan, United States

The SMART CART Study: Health Information Technology

Not Applicable

Completed

Conditions: Leukemia, Lymphoblastic
Leukemia, Acute

Interventions: Behavioral: Education information system
Other: Activity monitor
Other: Interview
Other: Survey Administration
Other: Laboratory Biomarker Analysis

First Posted Date: 2019-08-09

Last Posted Date: 2024-03-22

Lead Sponsor: University of Michigan Rogel Cancer Center

Target Recruit Count: 148

Registration Number: NCT04051216

Locations: 🇺🇸
University of Michigan, Ann Arbor, Michigan, United States

Nivolumab and the Antagonistic CSF-1R Monoclonal Antibody Cabiralizumab (BMS-986227) in Patients With Relapsed/Refractory Peripheral T Cell Lymphoma

Phase 2

Completed

Conditions: Peripheral T Cell Lymphoma

Interventions: Drug: Nivolumab
Drug: cabiralizumab

First Posted Date: 2019-04-25

Last Posted Date: 2024-03-18

Lead Sponsor: University of Michigan Rogel Cancer Center

Target Recruit Count: 4

Registration Number: NCT03927105

Locations: 🇺🇸
Unviersity of Wisconsin, Madison, Wisconsin, United States
🇺🇸
University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States
🇺🇸
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States

Vorinostat for Graft vs Host Disease Prevention in Children, Adolescents and Young Adults Undergoing Allogeneic Blood and Marrow Transplantation

Phase 1

Active, not recruiting

Conditions: Hematologic Diseases
Chronic Myelogenous Leukemia, Accelerated Phase
Myelodysplastic Syndromes
Mantle Cell Lymphoma
Follicular Lymphoma
Diffuse Large B Cell Lymphoma
Graft Vs Host Disease
Acute Leukemia in Remission
Chronic Myelogenous Leukemia, Blastic Phase
Non Hodgkin Lymphoma

Interventions: Drug: Vorinostat
Procedure: Blood and Marrow Transplant (BMT)
Drug: Tacrolimus (or cyclosporine)
Drug: Methotrexate
Drug: Mycophenolate Mofetil (MMF)
Drug: Cyclophosphamide

First Posted Date: 2019-02-15

Last Posted Date: 2025-04-08

Lead Sponsor: University of Michigan Rogel Cancer Center

Target Recruit Count: 43

Registration Number: NCT03842696

Locations: 🇺🇸
University of Colorado, Aurora, Colorado, United States
🇺🇸
Emory University, Atlanta, Georgia, United States
🇺🇸
Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, Indiana, United States

and more 4 locations

Radiotherapy, Carboplatin/Paclitaxel and Nivolumab for High Risk HPV-related Head and Neck Cancer

Phase 2

Active, not recruiting

Conditions: Oropharynx Squamous Cell Carcinoma

Interventions: Drug: Nivolumab
Drug: Carboplatin
Drug: Paclitaxel
Radiation: Radiation Therapy

First Posted Date: 2019-02-04

Last Posted Date: 2024-03-18

Lead Sponsor: University of Michigan Rogel Cancer Center

Target Recruit Count: 26

Registration Number: NCT03829722

Locations: 🇺🇸
University of Michigan Rogel Cancer Center, Ann Arbor, Michigan, United States

Targeting Resistant Prostate Cancer With ATR and PARP Inhibition (TRAP Trial)

Phase 2

Active, not recruiting

Conditions: Prostate Cancer

Interventions: Drug: Olaparib
Drug: AZD6738

First Posted Date: 2018-12-26

Last Posted Date: 2025-03-28

Lead Sponsor: University of Michigan Rogel Cancer Center

Target Recruit Count: 49

Registration Number: NCT03787680

Locations: 🇺🇸
University of Michigan Hospital, Ann Arbor, Michigan, United States
🇺🇸
University of Virginia Health System, Charlottesville, Virginia, United States
🇺🇸
Wayne State University/Karmanos Cancer Institute, Detroit, Michigan, United States

Phase Ib/II Trial of Nal-Irinotecan and Nivolumab as Second-Line Treatment in Patients With Advanced Biliary Tract Cancer

Phase 1

Completed

Conditions: Biliary Tract Cancer

Interventions: Drug: Nivolumab
Drug: Nanoliposomal-Irinotecan
Drug: 5-Fluorouracil
Drug: Leucovorin

First Posted Date: 2018-12-24

Last Posted Date: 2024-12-18

Lead Sponsor: University of Michigan Rogel Cancer Center

Target Recruit Count: 34

Registration Number: NCT03785873

Locations: 🇺🇸
University of Michigan Rogel Cancer Center, Ann Arbor, Michigan, United States
🇺🇸
Cancer and Hematology Centers of Western Michigan, Grand Rapids, Michigan, United States
🇺🇸
University of Utah, Salt Lake City, Utah, United States

and more 2 locations

APG-115 in Salivary Gland Cancer Trial

Phase 1

Active, not recruiting

Conditions: Malignant Salivary Gland Cancer
Salivary Gland Cancer

Interventions: Drug: APG-115
Drug: Carboplatin

First Posted Date: 2018-12-20

Last Posted Date: 2025-01-14

Lead Sponsor: University of Michigan Rogel Cancer Center

Target Recruit Count: 41

Registration Number: NCT03781986

Locations: 🇺🇸
University of Chicago, Chicago, Illinois, United States
🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States
🇺🇸
University of Michigan Rogel Cancer Center, Ann Arbor, Michigan, United States

Acupressure for Fatigue in Ovarian Cancer Survivors

Not Applicable

Completed

Conditions: Fatigue
Ovarian Cancer

Interventions: Other: Sham acupressure
Other: Acupressure
Other: Standard of Care

First Posted Date: 2018-12-04

Last Posted Date: 2024-07-10

Lead Sponsor: University of Michigan Rogel Cancer Center

Target Recruit Count: 170

Registration Number: NCT03763838

Locations: 🇺🇸
University of Michigan Rogel Cancer Center, Ann Arbor, Michigan, United States

Home Terms & Conditions Privacy Policy